http://archpedi.jamanetwork.com/ en-us Sat, 01 Dec 2012 00:00:00 GMT Tue, 01 Jan 2013 00:51:52 GMT Silverchair editor@archpedi.jamanetwork.com webmaster@archpedi.jamanetwork.com http://archpedi.jamanetwork.com/article.aspx?articleID=352611 Fri, 01 Dec 2000 00:00:00 GMT Mier RJ, Bachrach SJ, Lakin RC, et al. <span class="paragraphSection"><div class="boxTitle">Objective</div>To determine the safety and efficacy of glycopyrrolate in the treatment of developmentally disabled children with sialorrhea.<div class="boxTitle">Design</div>Placebo-controlled, double-blind, crossover dose-ranging study.<div class="boxTitle">Setting</div>Outpatient facilities in 2 pediatric hospitals.<div class="boxTitle">Patients</div>Thirty-nine children with both developmental disabilities and excessive and bothersome sialorrhea.<div class="boxTitle">Main Outcome Measures</div>Parent and investigator evaluation of change in sialorrhea and adverse effects.<div class="boxTitle">Results</div>Glycopyrrolate in doses of 0.10 mg/kg per dose is effective at controlling sialorrhea. Even at low doses, 20% of children may exhibit adverse effects severe enough to require discontinuation.<div class="boxTitle">Conclusions</div>Glycopyrrolate is effective in the control of excessive sialorrhea in children with developmental disabilities. Approximately 20% of children given glycopyrrolate may experience substantial adverse effects, enough to require discontinuation of medication.</span> 154 12 1214 1218 10.1001/archpedi.154.12.1214 http://archpedi.jamanetwork.com/article.aspx?articleID=352611